U.S. Bioscience lodenosine
Executive Summary
Interim 12-week Phase II data show 55% of patients receiving lodenosine as part of a triple combination therapy experienced a reduction in HIV-RNA levels below 50 copies/mL vs. 50% of patients randomized to receive 3TC after 12 weeks of therapy. All patients were given d4T and indinavir (Merck's Crixivan). No adverse events reported have been attributed to lodenosine. The percentage of patients who have discontinued the study is 7.1% (lodenosine 100 mg), 10% (lodenosine 200 mg), 13.3% (lodenosine 300 mg) and 21.1% (control). Results from 24-week evaluations are anticipated next year, U.S. Bioscience said. U.S. Bioscience is in the process of being acquired by MedImmune (1"The Pink Sheet" Sept. 27, p. 21)
You may also be interested in...
MedImmune Gets Closer To Abbott With U.S. Bioscience Merger
MedImmune's acquisition of U.S. Bioscience will likely lead to a tighter relationship with Abbott. Abbott already co-markets MedImmune's Synagis (palivizumab) and is in the process of acquiring Alza, which co-promotes U.S. Bioscience's top product Ethyol (amifostine) in the U.S.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials